NL

Nanna Luneborg

General Partner at Forbion

Amsterdam, North Holland

Overview 

Nanna Luneborg is a General Partner at Forbion in Amsterdam, with a strong background in venture capital and extensive experience in the pharmaceutical and biotechnology industries. She has successfully invested in companies like Capstan Therapeutics and Noema Pharma, demonstrating a track record of strategic decision-making and financial acumen in her role. With a Master of Business Administration from the University of Cambridge and a PhD from UCL, Nanna has excelled in various positions at Novo Holdings and Apposite Capital, showcasing her expertise in due diligence, market analysis, and valuation within the healthcare sector.

Work Experience 

F

Forbion

  • General Partner

    2021 - Current

    - General Partner, Forbion Growth Opportunities Fund - Late stage and crossover investments in biotech - Board director of Capstan, BioInvent, F2G, Noema and Inversago (acquired by Novo Nordisk), observer in Numab

NH

Novo Holdings

  • Partner

    2018 - 2021

    • Partner in Novo Ventures • Board director in Numab, Lava (LVTX), ReViral (acquired by Pfizer), NodThera and Stargazer • Previous deals as lead investor/board director include NBE Therapeutics (acquired by Boehringer Ingelheim), Inventiva (IVA), Orphazyme (ORPHA), ObsEva (OBSV) and IO Biotech (IOBT)

  • Principal

    2016 - 2017

    • Principal in Novo Ventures

  • Investment Director

    2013 - 2015

    • Investment Director in Novo Seeds • Board member in IO Biotech, Inthera, Glionova, Affinicon, MinervaX, Pcovery, board observer in Galecto, ForEndo

  • Principal

    2012 - 2013

    • Principal in Novo Seeds • Seed stage biotech venture investment in Northern Europe

AC

Apposite Capital

  • Associate

    2008 - 2012

    • Investment professional in a healthcare venture fund • Successful exits from both primary and secondary deals, incl Convergence, Ulthera, SureCalm • Multiple deals completed from initial diligence to closing • Various deal structures: primary/secondary investments, spin-out, start-up, management buy-in

AC

Apposite Capital

  • Intern

    2008 - 2008

    MBA summer internship

C

Cisco

  • Consulting project

    2008 - 2008

    MBA team consulting project: IP technology in UK healthcare

Cisco DevNet is your source for everything developer at Cisco Systems.

developer.cisco.com

Aktogen

  • Consulting project

    2007 - 2007

    MBA team consulting project on business model and strategy for a biotech start-up

CR

Cancer Research UK

  • Senior Business Intelligence Analyst

    2006 - 2007

    • Business Intelligence on performance metrics across £315 M research portfolio • Strategic evaluation to CEO

  • Research Manager

    2005 - 2006

    • Financial and scientific analyses of research portfolio across organisation • Liaison with principal investigators and research organisations in UK and US

UC

University College London

  • Graduate Research Associate

    2000 - 2004

    Research project leading to PhD thesis in development neuroscience

I

IIR

  • Marketing Manager

    1996 - 1997

    Managed marketing campaigns for international business conference and training group

Education 

Investments 

Capstan Therapeutics

Series B

Total funding: $280M

Noema Pharma

Series B

Total funding: $110M

Inversago Pharma

Series C

Total funding: $110M

F2G

Private Equity

Total funding: $160M

Articles About Nanna

Relevant Websites